These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 28138221)

  • 1. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.
    Françoso A; Simioni PU
    Drug Des Devel Ther; 2017; 11():177-184. PubMed ID: 28138221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of monoclonal antibodies for the treatment of colorectal cancer.
    Goodin S
    Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S3-7; quiz S22-4. PubMed ID: 18499888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.
    Mauri G; Pizzutilo EG; Amatu A; Bencardino K; Palmeri L; Bonazzina EF; Tosi F; Carlo Stella G; Burrafato G; Scaglione F; Marsoni S; Siravegna G; Bardelli A; Siena S; Sartore-Bianchi A
    Cancer Treat Rev; 2019 Feb; 73():41-53. PubMed ID: 30616224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab a novel drug in cancer treatment.
    Cartenì G; Fiorentino R; Vecchione L; Chiurazzi B; Battista C
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi16-21. PubMed ID: 17591813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer.
    Saoudi Gonzalez N; López D; Gómez D; Ros J; Baraibar I; Salva F; Tabernero J; Élez E
    Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):755-767. PubMed ID: 36582117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular target therapy and chemotherapy for advanced colorectal cancer].
    Nakashima K; Yamazaki K; Boku N
    Gan To Kagaku Ryoho; 2008 May; 35(5):725-30. PubMed ID: 18487907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
    Snyder LC; Astsaturov I; Weiner LM
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies in the treatment of advanced colorectal cancer.
    Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
    Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.
    Rivera F; Vega-Villegas ME; Lopez-Brea MF; Marquez R
    Acta Oncol; 2008; 47(1):9-19. PubMed ID: 18097777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies for targeted therapy in colorectal cancer.
    Banerjee S; Flores-Rozas H
    Cancer Biol Ther; 2010 Apr; 9(8):563-71. PubMed ID: 20200482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
    Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
    Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.